S.M.B. is a Belgian based pharmaceutical company with global ambitions. Its objective is to become a leading European player in the field of oral and pulmonary drug delivery systems by being an innovative actor in the pharmaceutical industry.
Together with its exclusive partners, S.M.B. Technology S.A. (Contract Manufacturing) and GALEPHAR M/F (Contract R&D), Laboratoires SMB’s activity embraces a large spectrum of competences in initial R&D, continuous R&D, Clinical Trials, Analytics, production, Regulatory Affairs and Marketing, supporting a pipeline of in-house formulations.
Manufacturing site in Marche-En-Famenne, Belgium
For more than 50 years, S.M.B. has used its experience, know-how and state of the art technologies to identify and develop its own Drug Delivery Systems designed for a selected active ingredient to improve patients’ outcomes:
In S.M.B., R&D is by essence the core activity, a token for its independence as small medium sized company.
Thanks to the success of its R&D Department, S.M.B. has become internationally recognized in the field of human health care in various high-tech areas such as Micropellets (microgranules for once daily administration), Lidose® (semi-solid lipidic matrix in hard capsule formulation), Divule® (high gloss gelatine coated tabs), DPI (Dry Powder Inhaler) and Effervescent Tablets design and large scale production.
S.M.B. proposes a balanced portfolio of products mainly in: